Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2004 6
2005 5
2006 4
2007 2
2008 4
2009 1
2011 5
2012 3
2013 5
2014 8
2015 7
2016 9
2017 8
2018 13
2019 8
2020 10
2021 8
2022 7
2023 12
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean naoko ogata (4 results)?
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Reply.
Yoshikawa T, Obayashi K, Ogata N. Yoshikawa T, et al. Among authors: ogata n. Ophthalmology. 2020 May;127(5):e31-e32. doi: 10.1016/j.ophtha.2020.01.013. Ophthalmology. 2020. PMID: 32327140 No abstract available.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Among authors: ogata n. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Ophthalmology. 2023 Dec 28:S0161-6420(23)00933-8. doi: 10.1016/j.ophtha.2023.12.026. Online ahead of print. Ophthalmology. 2023. PMID: 38158159 Free article.
Best surgical technique and outcomes for large macular holes: retrospective multicentre study in Japan.
Yamashita T, Sakamoto T, Terasaki H, Iwasaki M, Ogushi Y, Okamoto F, Takeuchi M, Yasukawa T, Takamura Y, Ogata N, Nakamura Y; writing committee of Japan-Clinical Retina Research Team (J-CREST). Yamashita T, et al. Among authors: ogata n. Acta Ophthalmol. 2018 Dec;96(8):e904-e910. doi: 10.1111/aos.13795. Epub 2018 Apr 19. Acta Ophthalmol. 2018. PMID: 29671948 Free article. Review.
Severe panuveitis with relapsing polychondritis.
Masuda N, Nishikawa R, Ueda T, Ogata N. Masuda N, et al. Among authors: ogata n. Am J Ophthalmol Case Rep. 2018 Apr 20;11:3-5. doi: 10.1016/j.ajoc.2018.04.024. eCollection 2018 Sep. Am J Ophthalmol Case Rep. 2018. PMID: 30050999 Free PMC article.
Retinal thickness in children with anisohypermetropic amblyopia.
Nishi T, Ueda T, Hasegawa T, Miyata K, Ogata N. Nishi T, et al. Among authors: ogata n. Br J Ophthalmol. 2015 Aug;99(8):1060-4. doi: 10.1136/bjophthalmol-2014-305685. Epub 2015 Feb 13. Br J Ophthalmol. 2015. PMID: 25680622
119 results